Gussin brings over 20 years of innovation and product development expertise within diagnostics and life sciences to spearhead BioFlyte’s product roadmap and commercialization efforts

BioFlyte, a bioaerosol surveillance firm with a disruptive new class of fieldable biological threat collection, detection, and identification solutions, today announced the appointment of Daniel (Dan) Gussin as Vice President of Product. In this role, Gussin will lead the company’s product development roadmap and commercialization efforts to ensure that its evolving capabilities continue to exceed customer expectations.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230906523709/en/

Dan Gussin has joined BioFlyte as Vice President of Product. In this role, Gussin will lead the company’s product development roadmap and commercialization efforts to ensure that its evolving capabilities continue to exceed customer expectations. (Photo: Business Wire)

Gussin has more than two decades of proven experience leading product development efforts within the diagnostics and life sciences industries and brings both technical and leadership skills to BioFlyte. Most recently, he served as the Director of Product and Program Management and the Interim Head of Quality at Genalyte Inc., a leading diagnostics and analytics company. He owned the product lifecycle and spearheaded multiple technical programs to increase manufacturing yield and throughput, leading to significant reductions in production costs.

As a Senior Program Manager and Engineering Lead at TE Connectivity, a global in-vitro diagnostic (IVD) and life science engineering consultancy for product design and manufacturing development, Gussin developed and implemented product strategies from concept to FDA submission and commercialization. He also worked with the U.S. Department of Health and Human Services’ Biomedical Advanced Research and Development Authority (BARDA) on several biothreat sampling detection and identification products, resulting in FDA regulatory approved devices and additional funding. Prior to TE, Gussin also held product development leadership roles at several other diagnostics companies, including Xagenic, Segasist, Alere and Xceed Molecular.

“Following our move to a new, larger facility and raising our Series B financing, BioFlyte is in a true growth period, and we are looking to expand our product innovation and development efforts as we increase our market presence,” said Todd Sickles, CEO of BioFlyte. “Dan is a skilled leader who can operate across multiple teams as an expert in diagnostic product design and development, as well as product commercialization. I am glad to welcome him to our leadership team and look forward to seeing how our product roadmap and commercial efforts will flourish under his guidance.”

“BioFlyte’s technology has the potential to transform the way we protect critical infrastructure and keep people in those environments safe,” said Gussin. “BioFlyte’s mission is strongly aligned with my personal values and passion for next generation diagnostics and novel sensor technology. I am excited to bring my experience developing and executing on product innovation strategies to push the company toward sustainable and scalable growth.”

To learn more about BioFlyte, please visit https://bioflyte.com.

About BioFlyte

BioFlyte is a bioaerosol surveillance company that is commercializing a revolutionary new class of fieldable biological contamination sampling, detection, and identification solutions. The firm’s current market focus is critical infrastructure protection and mail screening in both the government and commercial sectors. For more information about BioFlyte and its products, please visit: https://bioflyte.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230906523709/en/